Fair points muya . The share price is almost exactly where it...

Fair points muya . The share price is almost exactly where it was in October 2011 so zero value added in almost 10 years so I can’t argue your facts.
The 1a life saving ICU device is a superb product that has carried the company but I am hopeful the new approval of devices and regions will help lift the sales and revenues which as you and nilnoony state are the be all and end all re credibility. I believe the bp plus was ce Mark approved for European sales back in December 2017 so not sure how much that has contributed re revenues. I think the 1a has been the shining light but perhaps the bp plus has had more European sales over the 3 1/2 yearsthen it seems to have had.
@nilnoony . Thanks for the heads up re today’s interview. Just listened. Solid and upbeat as always. Was not aware that the Uscom 1a was already in 40% of the top U.S hospitals. Credibility right there.
The interview lady pushed hard on the is it an Australian product made locally. I find it strange that the locally made devices like the 1a and bp plus get sold around the world but my local hospitals and doctor clinics don’t use them. So much for supporting life saving Australian medical devices but that’s another story across many industries that frustrates me.
Hopefully if they are able put the interview on their Facebook, LinkedIn and Twitter sites for extra exposure. They have failed to put the last 2 announcements on AAA credit and Russian approval on any so perhaps they won’t.
I agree- Sales , Revenues, Profits!!!!